Plain-English translation of NCT05135091 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , an experimental cell therapy designed to reduce seizures in people whose epilepsy hasn't responded well to medications. Doctors will inject special brain cells directly into the area where your seizures start; these cells release a natural calming chemical in the brain that helps prevent seizures from occurring. The study will track your seizure frequency and safety for up to 15 years after the injection.
Many people with temporal lobe epilepsy continue to have frequent, disabling seizures even after trying multiple anti-seizure medications. This medication offers a new approach—instead of just taking pills, it aims to directly calm the brain region causing the seizures by introducing cells that naturally suppress abnormal electrical activity.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a one-time injection of the medication directly into your brain under imaging guidance—a surgical procedure done in a hospital. You'll then take immune-suppressing medication for one year to help the injected cells survive long-term. Over the first 2 years, you'll have regular clinic visits to check your seizure frequency, safety, and side effects. After that, you'll continue with quarterly phone calls and annual visits through year 5, then annual visits through year 15.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States